dan 2163 has been researched along with Dysthymic Disorder in 12 studies
Dysthymic Disorder: Chronically depressed mood that occurs for most of the day more days than not for at least 2 years. The required minimum duration in children to make this diagnosis is 1 year. During periods of depressed mood, at least 2 of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self-esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. (DSM-IV)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a multicentre, 3-month, placebo-controlled study, amisulpride (50 mg/day) was compared to amineptine (200 mg/day) in the treatment of primary dysthymia." | 9.09 | Amisulpride versus amineptine and placebo for the treatment of dysthymia. ( Boyer, P; Fleurot, O; Lecrubier, Y; Stalla-Bourdillon, A, 1999) |
| "Two hundred and fifty patients participated in a 6-month, double-blind study to evaluate safety and efficacy of a medium-term treatment with amisulpride 50 mg/day versus amitriptyline 25-75 mg/day in dysthymia." | 9.09 | Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. ( Ravizza, L, 1999) |
| "In a multicentre, double blind, parallel group study 281 patients with DSM III-R diagnosis of dysthymia or a single episode of major depression in partial remission were randomised to 3 months of treatment with amisulpride 50 mg/day or fluoxetine 20 mg/day." | 9.08 | Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. ( Smeraldi, E, 1998) |
| "Dysthymic disorder is a chronic depressive condition with considerable psychosocial impairment." | 6.70 | A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. ( Bogetto, F; Marchiaro, L; Rasetti, R; Rivoira, E; Rocca, P, 2002) |
| " In a multicentre, 3-month, placebo-controlled study, amisulpride (50 mg/day) was compared to amineptine (200 mg/day) in the treatment of primary dysthymia." | 5.09 | Amisulpride versus amineptine and placebo for the treatment of dysthymia. ( Boyer, P; Fleurot, O; Lecrubier, Y; Stalla-Bourdillon, A, 1999) |
| "Two hundred and fifty patients participated in a 6-month, double-blind study to evaluate safety and efficacy of a medium-term treatment with amisulpride 50 mg/day versus amitriptyline 25-75 mg/day in dysthymia." | 5.09 | Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. ( Ravizza, L, 1999) |
| "In a multicentre, double blind, parallel group study 281 patients with DSM III-R diagnosis of dysthymia or a single episode of major depression in partial remission were randomised to 3 months of treatment with amisulpride 50 mg/day or fluoxetine 20 mg/day." | 5.08 | Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. ( Smeraldi, E, 1998) |
| "Dysthymic disorder is a chronic depressive condition with considerable psychosocial impairment." | 2.70 | A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. ( Bogetto, F; Marchiaro, L; Rasetti, R; Rivoira, E; Rocca, P, 2002) |
| "It appears to be an effective agent in treating schizophrenia for what are characterised as positive and negative symptoms." | 2.41 | Focus on amisulpride. ( Green, B, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carta, MG | 1 |
| Paribello, P | 1 |
| Nardi, AE | 1 |
| Preti, A | 1 |
| Komossa, K | 1 |
| Depping, AM | 1 |
| Gaudchau, A | 1 |
| Kissling, W | 1 |
| Leucht, S | 1 |
| Rocca, P | 2 |
| Fonzo, V | 1 |
| Ravizza, L | 2 |
| Rocca, G | 1 |
| Scotta, M | 1 |
| Zanalda, E | 1 |
| Bogetto, F | 2 |
| Marchiaro, L | 1 |
| Rasetti, R | 1 |
| Rivoira, E | 1 |
| Montgomery, SA | 1 |
| Zanardi, R | 1 |
| Smeraldi, E | 2 |
| Boyer, P | 1 |
| Lecrubier, Y | 1 |
| Stalla-Bourdillon, A | 1 |
| Fleurot, O | 1 |
| Amore, M | 1 |
| Jori, MC | 1 |
| Pani, L | 1 |
| Gessa, GL | 1 |
| Green, B | 1 |
5 reviews available for dan 2163 and Dysthymic Disorder
| Article | Year |
|---|---|
Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Dysthymic Diso | 2019 |
Second-generation antipsychotics for major depressive disorder and dysthymia.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive | 2010 |
Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.
Topics: Amisulpride; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; D | 2002 |
The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia.
Topics: Amisulpride; Antidepressive Agents; Benzamides; Dysthymic Disorder; Humans; Receptors, Dopamine D1; | 2002 |
Focus on amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Controlled Clinical Trials as Topic; Dysthymic Disorder; Humans; | 2002 |
7 trials available for dan 2163 and Dysthymic Disorder
| Article | Year |
|---|---|
A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder.
Topics: Administration, Oral; Adult; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Ag | 2002 |
A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Drug Therapy, Co | 2002 |
A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia.
Topics: Acetylcarnitine; Adolescent; Adult; Amisulpride; Antipsychotic Agents; Demography; Double-Blind Meth | 2006 |
Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study.
Topics: Adolescent; Adult; Aged; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents | 1998 |
Amisulpride versus amineptine and placebo for the treatment of dysthymia.
Topics: Amisulpride; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Dibenzocycloheptenes; Double-Bl | 1999 |
Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators.
Topics: Adult; Aged; Amisulpride; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Dou | 1999 |
Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study.
Topics: Adolescent; Adult; Aged; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Depressive Disord | 2001 |